Mistral Ventures, Inc. Nature s Bioceuticals, Inc. (A Development Stage Company)

Size: px

Start display at page:

Download "Mistral Ventures, Inc. Nature s Bioceuticals, Inc. (A Development Stage Company)"

Penelope Lambert
5 years ago
Views:

1 Financial Statements For the Period Ended June 30, 2012 (unaudited prepared by H & M Accounting and Tax Services, Inc. Delray, Florida and management)... 2 Statements of Operations... 3 Statements of Cash Flows... 4 Notes to the Financial Statements...

2 ASSETS December 31, March 31, June 30, Cash 181, , , Inventory - 3, , Prepaid Expenses 28, , , Total Current Assets 209, , , Equipment- net Depr 3, , , Formula 985, , , Total Fixed Assets 988, , , Total Assets 1,197, ,182, ,126, Current Liabilites Taxes Payable Total Liabiilities STOCKHOLDERS EQUITY Common Stock authorized 1,125,000,000 common shares with a par Value of $ issued and outstanding 961,230,600 / 962,230,600, Additional Paid in Capital 1,227, ,277, ,277, Retained Earnings (deficit) (30,643.00) (96,046.00) (151,653.00) Total Stockholders Equity 1,197, ,182, ,126, Total Liabilities & Equity 1,197, ,182, ,126,

3 Statement of Operations Revenue For the year Ended December 31, 2011 For the Three months Ended March 31, 2012 For the Three months Ended June 30, 2012 For the Six Months ended June 30, 2012 Sales , , Cost of Sales , Gross Profit , Operating Expenses Management Expense 15, , , , General and Administrative 15, , , , total operating Expenses 30, , , , Net Loss for period (30,643.00) (65,403.00) (55,609.00) (121,012.00) Net loss per share ( ) ( ) ( ) ( ) 3

4 Statement of Cash Flows Operating Activities For the year Ended December 31, 2011 For the Three Months Ended March 31, 2012 Three Months Ended June 30, 2012 Six Months Ended June 30, 2012 Net Loss (30,643.00) (65,403.00) (55,609.00) (121,012.00) Purchase of Formulas (985,000.00) Purchase of Equipment (3,186.00) Advanced Commissions (28,000.00) Depreciation , Inventory (3,500.00) (1,063.00) (4,563.00) Increase in Liabilities Net cash provided (used) by Operations (1,046,829.00) (68,103.00) (55,874.00) (123,977.00) Investing Activities Proceeds from Issuance of Stock 1,228, , , Increase (Decrease) in Cash 181, (18,103.00) (55,874.00) (73,977.00) Beginning Cash Balance 181, , , Ending Cash Balance 181, , , ,

5 1. Nature of Operations and Continuance of Business (the Company ) was incorporated in the State of Florida on December 27, The Company is a development stage company, as defined by Financial Accounting Standards Board ( FASB ) Accounting Standards Codification ( ASC ) 915, Development Stage Entities. Going Concern These financial statements have been prepared on a going concern basis, which implies that the Company will continue to realize its assets and discharge its liabilities in the normal course of business. As of December 31, 2011 the Company has not recognized any revenue, and has an accumulated deficit of $30,643.. The continuation of the Company as a going concern is dependent upon the continued financial support from its management, and its ability to identify future investment opportunities and obtain the necessary debt or equity financing, and generating profitable operations from the Company s future operations. These factors raise substantial doubt regarding the Company s ability to continue as a going concern. These financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. 2. Summary of Significant Accounting Policies a) Basis of Presentation The financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States ( US GAAP ) and are expressed in U.S. dollars. The Company s fiscal year end is December 31. b) Use of Estimates The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions related to the deferred income tax asset valuation allowances. The Company bases its estimates and assumptions on current facts, historical experience and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company s estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected. c) Cash and cash equivalents The Company considers all highly liquid instruments with a maturity of three months or less at the time of issuance to be cash equivalents. d) Second Quarter 2012 Financial Statements These financial statements and in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary to present fairly the Company s financial position, results of operations and cash flows for the period shown. 2. Summary of Significant Accounting Policies (continued) e) Basic and Diluted Net Loss per Share The Company computes net loss per share in accordance with ASC 260, Earnings per Share. ASC 260 requires presentation of both basic and diluted earnings per share ( EPS ) on the face of the income 5

6 statement. Basic EPS is computed by dividing net loss available to common shareholders (numerator) by the weighted average number of shares outstanding (denominator) during the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period using the treasury stock method and convertible preferred stock using the if-converted method. In computing diluted EPS, the average stock price for the period is used in determining the number of shares assumed to be purchased from the exercise of stock options or warrants. Diluted EPS excludes all dilutive potential shares if their effect is anti dilutive. f) Financial Instruments Pursuant to ASC 820, Fair Value Measurements and Disclosures, an entity is required to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 establishes a fair value hierarchy based on the level of independent, objective evidence surrounding the inputs used to measure fair value. A financial instrument s categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. ASC 820 prioritizes the inputs into three levels that may be used to measure fair value: Level 1 Level 1 applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities. Level 2 Level 2 applies to assets or liabilities for which there are inputs other than quoted prices that are observable for the asset or liability such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data. Level 3 Level 3 applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities. The Company s financial instruments consist principally of cash, accounts payable, and amounts due to a related party if any. Pursuant to ASC 820, the fair value of our cash is determined based on Level 1 inputs, which consist of quoted prices in active markets for identical assets. We believe that the recorded values of all of our other financial instruments approximate their current fair values because of their nature and respective maturity dates or durations. g) Property and Equipment Property and equipment is comprised of assets acquired from a patent pending Breathing, Sinus, Kidney, Weight Loss, Cold & Flu Formula's and office equipment. Office equipment is being amortized straight-line over three years from the date of acquisition, and the breathing formula will be amortized straight-line over ten years once the formulas has been put into use. In accordance with ASC 360, Property Plant and Equipment, management tests long-lived assets to be held and used for recoverability whenever events or changes in circumstances indicate that their carrying amount may not be recoverable. 2. Summary of Significant Accounting Policies (continued) h) Comprehensive Loss ASC 220, Comprehensive Income, establishes standards for the reporting and display of comprehensive loss and its components in the financial statements. As of June 30, 2012, the Company has no items that represent a comprehensive loss and, therefore, has not included a schedule of comprehensive loss in the financial statements. 6

7 i) Recent Accounting Pronouncements The Company has implemented all new accounting pronouncements that are in effect. These pronouncements did not have any material impact on the financial statements unless otherwise disclosed, and the Company does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its financial position or results of operations. 3. Property and Equipment Cost $ Formula's 985,000 Office equipment 3, , Related Party Transactions: None 5. Subsequent Events On October 17, 2011, Mistral Ventures, Inc. ( Mistral or the Company ) entered into a share exchange agreement with ( NBI ), a private corporation formed under the state of Florida. Under the terms of the agreement, Mistral will acquire 100% of the issued and outstanding common shares of NBI in exchange for 652,780,600 common shares of the Company. After the close of the share exchange agreement, the former shareholders of NBI will control approximately 72% of the total issued and outstanding common shares of Mistral, resulting in a reverse takeover. At the time of the share exchange agreement Mistral Ventures had 590,000,000 shares issued and outstanding. As part of the share exchange agreement Mistral Ventures was required to cancel 338,000,000 shares held by Srinivas Polishetty leaving a balance of 252,000,000 issued and outstanding. As of 12/31/11 287,550,000 have been returned to treasury so far. During the fourth quarter of 2011, the company received $300,000 by wire transfer equaling 6,000,000 Shares of full-paid common stock of Mistral Ventures. Inc. As a result of these transactions as of December 31, 2011 the Company has 961,230,600 Shares of Common Stock outstanding but only 302,450,000, that were issued to MILV shareholders of record prior to the share exchange, are issued. We have yet to convert and issue 652,780,600 to Nature's Bioceuticals share holders and have yet to issue the above 6,000,000 common shares. During the 1st quarter of 2012 the company received $50,000 by wire transfer equaling 1,000,000 Shares of full-paid common stock of Mistral Ventures. Inc. As a result of these transactions as of March 31, 2012 the Company has 962,230,600 Shares of Common Stock outstanding but only 302,450,000, that were issued to MILV shareholders of record prior to the share exchange, are issued. We have yet to convert and issue 652,780,600 to Nature's Bioceuticals share holders and have yet to issue the above 7,000,000 common shares. During the 2nd Quarter of 2012 there is no new subsequent events. 7

CMG HOLDINGS GROUP INC Consolidated Balance Sheets

CMG HOLDINGS GROUP INC Consolidated Balance Sheets ASSETS BALANCE SHEETS Unaudited December 31, December 31, 2018 2017 CURRENT ASSETS Cash and Cash Equivalents $ 162,931 $ 39,566 Prepaid expenses and other